DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management.

ABSTRACT:

Background

Variability in standard-of-care classifications precludes accurate predictions of early tumor recurrence for individual patients with meningioma, limiting the appropriate selection of patients who would benefit from adjuvant radiotherapy to delay recurrence. We aimed to develop an individualized prediction model of early recurrence risk combining clinical and molecular factors in meningioma.

Methods

DNA methylation profiles of clinically annotated tumor samples across multiple institutions were used to develop a methylome model of 5-year recurrence-free survival (RFS). Subsequently, a 5-year meningioma recurrence score was generated using a nomogram that integrated the methylome model with established prognostic clinical factors. Performance of both models was eva

SUBMITTER: Nassiri F 

PROVIDER: S-EPMC6620635 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature